Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

China Medical Technologies Inc.

BioPhotonics
Oct 2011
China Medical Technologies Inc. (CMED) of Beijing, and Leica Biosystems, a division of Leica Microsystems of Wetzlar, Germany, will collaborate to develop and market fluorescence in situ hybridization (FISH) kits for the Leica Bond system, an automated staining platform. The companies will develop automated solutions for tissue sample tests on HER-2, EGFR and TOP2A genes, all of which play a role in targeted drug therapy for breast, lung and stomach cancer. They also will work on additional FISH applications. CMED will sell the kits in China, while Leica will have the option to sell them in the rest of the world.


Asia-Pacificautomated FISH kitsbiophotonicsbreast cancer drug therapyBusinesscancer therapy drugsChinaChina Medical Technologies Inc.CMEDcytologyEGFR geneEuropeFISH kitsGermanyHER-2 genehistopathologyimagingin vitro diagnosticsLeica BiosystemsLeica BONDLeica Microsystemslung cancer drug therapymicroscopesprenatal applicationsRapidScanstaining platformstomach cancer drug therapytissue sample testsTOP2A gene

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2017 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!